Immuneed appoints Alexander Kele as new CEO
February 3, 2025
Uppsala, Sweden – February 03, 2025
Immuneed, a leading provider of advanced immuno-toxicology services specialized on fresh whole blood analysis, is pleased to announce the appointment of Alexander Kele as Chief Executive Officer, effective immediately.
Mr Kele brings more than two decades of experience from life science and serving biotech and pharma customers internationally. He has held leading roles in business development, strategic planning, product management and marketing. His mission will be to grow Immuneed beyond the Nordic markets.
“We are very pleased to welcome Alexander as our new CEO,” says Camilla Huse Bondesson, Chairman of the Board of Directors of Immuneed. “His commercial experience spans different types of businesses, which has given him a deep understanding of the relationship between companies and the market. He has a commercial approach that will contribute to the company’s further growth.”
“Immuneed is well positioned with its ID.Flow® technology and its capability to analyze blood within minutes after sampling to address the needs of pharma, biotech and regulatory agencies in their endeavor to avoid late failures related to the safety and efficacy through physiologically relevant immuno-toxicology studies. I just couldn’t refuse the exciting offer of growing this business beyond the Nordic markets and I look forward to working with the talented team at Immuneed”, says Alexander Kele
The company also wants to thank the previous CEO, Camilla Oldgren for her leadership and commitment to building a foundation for the company’s continued operations.
About Immuneed
Immuneed is a specialized services provider that, through its innovative technology ID.flow®, offers drug developers physiologically relevant immunological assessments for preclinical-stage molecules. ID.Flow proudly aligns with the latest regulatory guidance, the New Approach Methodologies, and supports the 3Rs by reducing the number of animals used in research.
By utilizing fresh human blood, our expert team conducts comprehensive studies to analyze how a drug affects both the adaptive and innate immune responses, all from a single sampling. By interpreting the results, Immuneed provides relevant data to drug developers, assisting with IND filings and enhancing the safety and effectiveness of drug development in the preclinical stage.
Contact details for inquiries.
To know more about our offering visit us at www.immuneed.com or contact us at contact@immuneed.com
For investment-related opportunities please contact us at investment@immuneed.com